SynthesisPeerJ2026
Effect of sodium-glucose cotransporter-2 inhibitors on fracture risk in patients with type 1 diabetes receiving insulin-based therapy: a meta-analysis.
Synthesis in PeerJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sodium-glucose cotransporter-2 inhibitors (SGLT2i), a novel class of antihyperglycemic agents, have raised concerns regarding bone safety. This meta-analysis aimed to evaluate the specific effect of adjunctive SGLT2i therapy on fracture risk in patients with type 1 diabetes mellitus (T1DM). Methods: We systematically searched four databases (PubMed, Embase, Cochrane Library and Web of Science Core Collection) to identifyall eligible randomized controlled trials (RCTs) investigating SGLT2i as adjunctive therapy to insulin in T1DM. Fracture risk was defined as primary outcome, while glycemic parameters, non-glycemic outcomes, and other safety index serving as secondary endpoints. Pooled ORs (95% CIs) were calculated, with dose-stratified subgroup analyses. Risk of bias was assessed using the Cochrane Collaboration Risk-of-Bias tool (RoB 2). Results: Our analysis included 10 RCTs comprising 6,731 T1DM patients. All included studies were deemed to be at low or moderate risk of bias. Pooled analysis revealed no significant association between SGLT2i use and fracture risk (OR 0.98, 95% CI [0.63-1.51]). This null finding remained consistent across subgroup analyses. Fracture odds ratios in the low-, moderate-, and high-dose subgroups were 0.78 (95% CI [0.11-5.58]), 1.08 (95% CI [0.55-2.11]), and 0.90 (95% CI [0.50-1.63]), respectively. SGLT2i significantly improved glycemic control, including HbA1c, fasting plasma glucose, and time in range. It also reduced body weight and blood pressure. However, SGLT2i treatment increased the risk of diabetic ketoacidosis (OR 3.52, 95% CI [2.16-5.71]) and genital tract infections (OR 3.69, 95% CI [2.85-4.78]). Conclusion: This meta-analysis provides reassuring evidence that adjunctive SGLT2 inhibitor use is not associated with increased fracture risk in insulin-treated patients with T1DM patients. Nonetheless, the substantially elevated risks of diabetic ketoacidosis and genital tract infections necessitate vigilant clinical monitoring and risk mitigation strategies to ensure safe use of these agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.